Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

The document provides Canadian expert recommendations on managing adverse events (AEs) associated with sacituzumab govitecan (SG) in treating metastatic triple-negative breast cancer (mTNBC). It highlights the efficacy of SG, with clinical trials showing improved progression-free survival and overall survival compared to standard chemotherapy. Common AEs include neutropenia, diarrhea, nausea, fatigue, alopecia, and anemia. Management strategies involve dose adjustments, pre-infusion medications, and supportive treatments like granulocyte colony-stimulating factor (G-CSF) and loperamide. Despite potential severe AEs, SG offers a promising treatment option for patients with limited alternatives, emphasizing the need for effective toxicity management to maximize patient benefits.